Special Issues

Topic Collection: Current Novel Treatment of Patients with Ovarian Cancer

· Print Special Issue Flyer

· Deadline for manuscript submissions:  N/A


Special Issue Editor

Guest Editor


Prof. Dr. Samir A. Farghaly

The Joan and Sanford I. Weill Medical College of Cornell University/ Graduate School of Medical Sciences, The New York Presbyterian Hospital- Weill Cornell Medical Center, and Sandra and Edward Meyer Cancer Center, New York, NY- USA

Website | E-Mail

Interests: Gynecological cancers minimally invasive surgery; Ovarian cancer targeted therapy; Ovarian cancer precision medicine; Immuno-oncology; Genomic profiling of ovarian cancer; Ovarian cancer biomarkers



Dr. Scott M. Eisenkop

Women's Cancer Center, Southern California, 4835 Van Nuys Blvd, Suite 208, Sherman Oaks, CA 91403, USA

Website 

Interests: Hysterectomy; Lymph node dissection; Robot assisted surgery


Special Issue Information

Dear Colleagues,


Ovarian cancer is the seventh most common deathly cancer in women and accounted for almost 300,000 new cases, and almost 200,000 deaths annually worldwide in 2018.   In 2020, there will be approximately 21,750 new cases of ovarian cancer diagnosed and 13,940 ovarian cancer deaths in the USA. Primary debulking/cytoreductive surgery associated with a platinum/paclitaxel –based chemotherapy, is the standard care within treatment of advanced ovarian cancer (FIGO stage III and IV).  The surgery could be achieved through open ultra-radical laparotomy surgery, laparoscopy, or robot-assisted laparoscopic surgery.  Due to its late presentation, often stage III or IV, the prognosis is poor. Notwithstanding the good initial response to primary therapy, optimal debulking followed by the two-drug combination of carboplatin plus paclitaxel, responses are generally short-lived, and the clinical outcome is still unsatisfactory with median progression free survival rates from 16 to 21 months. Platinum resistant patients are often offered other chemotherapeutics, including doxorubicin, gemcitabine or topotecan monotherapy with PFS rates of 3-4 months. There is a pressing need to identify more efficient therapies. Anti-angiogenesis therapeutics, Bevacizumab cediranib, and trebananib offers relatively good results in both primary and recurrent ovarian cancer.  Attempts to optimize chemotherapy have included weekly scheduling of paclitaxel and intraperitoneal chemotherapy. Trials using angiogenesis inhibition and poly-ADP ribose polymerase (PARP) inhibitors that have been FDA-approved for maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: olaparib, rucaparib, and niraparib show an advantage in progression free survival. In addition, Trabectedin combined with liposomal doxorubicin play a role in patients with intermediate platinum sensitive disease. Hyper thermic intraperitoneal chemotherapy (HIPEC) and chemo-immunotherapy may become a promising therapy for the treatment of ovarian cancer.  This publication is most timely, as our current knowledge and understanding of screening, the pathophysiology of ovarian cancer, molecular aspects of cancer progression and metastasis, and advances in minimally invasive surgery technology, has led to significant improvement of the relevant treatment modalities, including promising targeted and personalized therapy.


Prof. Dr. Samir A. Farghaly

Guest Editor

 

Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. We normally offer a discount greater than 30% (APC: $850) to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.


Keywords

Ovarian cancer; Epithelial ovarian cancer; Optimal debulking surgery; Chemotherapy; HIPEC, Platinum-resistant ovarian cancer; Anti-angiogenesis; PARP inhibitors


Share This Special Issue

     



Please wait a minute...
For Selected: Toggle Thumbnails

Current Issue

  • Volume 42, Issue 2